TNFR1 determines progression of chronic liver injury in the IKKγ/Nemo genetic model

Cell Death and Differentiation

Volumn 20, Issue 11, 2013, Pages 1580-1592

  Cubero, F J ^a   Singh, A ^a   Borkham Kamphorst, E ^a   Nevzorova, Y A ^a   Al Masaoudi, M ^a   Haas, U ^a   Boekschoten, M V ^b   Gassler, N ^a   Weiskirchen, R ^a   Muller, M ^b   Liedtke, C ^a   Trautwein, C ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b WAGENINGEN UNIVERSITY   (Netherlands)

Author keywords

hepatitis; IKK Nemo; TNFR1; TRAIL

Indexed keywords

TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CELL DEATH; CELL INFILTRATION; CELL PROLIFERATION; CELL SPECIFICITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; FIBROGENESIS; GENETIC MODEL; IMMUNOCOMPETENT CELL; LIVER CELL; LIVER INJURY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH;

MUS;

ANIMALS; DISEASE PROGRESSION; I-KAPPA B KINASE; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG INJURY; MALE; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MODELS, GENETIC; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; SIGNAL TRANSDUCTION;

EID: 84885419703     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2013.112     Document Type: Article

References (46)

1. Karin M, Lin A. NF-kappaB at the crossroads of life and death. Nat Immunol 2002; 3: 221-227.
2. Pahl HL. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 1999; 18: 6853-6866.
3. Schmidt-Supprian M, Bloch W, Courtois G, Addicks K, Israel A, Rajewsky K et al. NEMO/IKK gamma-deficient mice model incontinentia pigmenti. Mol Cell 2000; 5: 981-992.
4. Li Q, Van Antwerp D, Mercurio F, Lee KF, Verma IM. Severe liver degeneration in mice lacking the IkappaB kinase 2 gene. Science 1999; 284: 321-325.
5. Tanaka M, Fuentes ME, Yamaguchi K, Durnin MH, Dalrymple SA, Hardy KL et al. Embryonic lethality, liver degeneration, and impaired NF-kappa B activation in IKK-beta-deficient mice. Immunity 1999; 10: 421-429.
6. Rudolph D, Yeh WC, Wakeham A, Rudolph B, Nallainathan D, Potter J et al. Severe liver degeneration and lack of NF-kappaB activation in NEMO/IKKgamma-deficient mice. Genes Dev 2000; 14: 854-862.
7. Beraza N, Ludde T, Assmus U, Roskams T, Vander Borght S, Trautwein C. Hepatocyte-specific IKK gamma/NEMO expression determines the degree of liver injury. Gastroenterology 2007; 132: 2504-2517.
8. Luedde T, Beraza N, Kotsikoris V, van Loo G, Nenci A, De Vos R et al. Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell 2007; 11: 119-132.
9. Liedtke C, Bangen JM, Freimuth J, Beraza N, Lambertz D, Cubero FJ et al. Loss of caspase-8 protects mice against inflammation-related hepatocarcinogenesis but induces non-apoptotic liver injury. Gastroenterology 2011; 141: 2176-2187.
10. Papa S, Bubici C, Zazzeroni F, Franzoso G. Mechanisms of liver disease: cross-talk between the NF-kappaB and JNK pathways. Biol Chem 2009; 390: 965-976.
11. Doi TS, Marino MW, Takahashi T, Yoshida T, Sakakura T, Old LJ et al. Absence of tumor necrosis factor rescues RelA-deficient mice from embryonic lethality. Proc Natl Acad Sci USA 1999; 96: 2994-2999.
12. Rosenfeld ME, Prichard L, Shiojiri N, Fausto N. Prevention of hepatic apoptosis and embryonic lethality in RelA/TNFR-1 double knockout mice. Am J Pathol 2000; 156: 997-1007.
13. Beraza N, Malato Y, Sander LE, Al-Masaoudi M, Freimuth J, Riethmacher D et al. Hepatocyte-specific NEMO deletion promotes NK/NKT cell-and TRAIL-dependent liver damage. J Exp Med 2009; 206: 1727-1737.
14. Kwon YH, Jovanovic A, Serfas MS, Tyner AL. The Cdk inhibitor p21 is required for necrosis, but it inhibits apoptosis following toxin-induced liver injury. J Biol Chem 2003; 278: 30348-30355.
15. Karlmark KR, Wasmuth HE, Trautwein C, Tacke F. Chemokine-directed immune cell infiltration in acute and chronic liver disease. Expert Rev Gastroenterol Hepatol 2008; 2: 233-242.
16. Onofre AS, Pomjanski N, Buckstegge B, Bocking A. Immunocytochemical diagnosis of hepatocellular carcinoma and identification of carcinomas of unknown primary metastatic to the liver on fine-needle aspiration cytologies. Cancer 2007; 111: 259-268.
17. Klein I, Cornejo JC, Polakos NK, John B, Wuensch SA, Topham DJ et al. Kupffer cell heterogeneity: functional properties of bone marrow derived and sessile hepatic macrophages. Blood 2007; 110: 4077-4085.
18. Legarda-Addison D, Hase H, O'Donnell MA, Ting AT. NEMO/IKKgamma regulates an early NF-kappaB-independent cell-death checkpoint during TNF signaling. Cell Death Differ 2009; 16: 1279-1288.
19. Yamaoka S, Courtois G, Bessia C, Whiteside ST, Weil R, Agou F et al. Complementation cloning of NEMO, a component of the IkappaB kinase complex essential for NF-kappaB activation. Cell 1998; 93: 1231-1240.
20. Chaisson ML, Brooling JT, Ladiges W, Tsai S, Fausto N. Hepatocyte-specific inhibition of NF-kappaB leads to apoptosis after TNF treatment, but not after partial hepatectomy. J Clin Invest 2002; 110: 193-202.
21. Aigelsreiter A, Haybaeck J, Schauer S, Kiesslich T, Bettermann K, Griessbacher A et al. NEMO expression in human hepatocellular carcinoma and its association with clinical outcome. Hum Pathol 2012; 43: 1012-1019.
22. Canbay A, Gieseler RK, Gores GJ, Gerken G. The relationship between apoptosis and non-alcoholic fatty liver disease: an evolutionary cornerstone turned pathogenic. Z Gastroenterol 2005; 43: 211-217.
23. Guo G, Morrissey J, McCracken R, Tolley T, Klahr S. Role of TNFR1 and TNFR2 receptors in tubulointerstitial fibrosis of obstructive nephropathy. Am J Physiol 1999; 277(5 Pt 2): F766-F772.
24. Klein C, Wustefeld T, Assmus U, Roskams T, Rose-John S, Muller M et al. The IL-6-gp 130-STAT3 pathway in hepatocytes triggers liver protection in T cell-mediated liver injury. J Clin Invest 2005; 115: 860-869.
25. Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007; 317: 121-124.
26. Gao B. Cytokines, STATs and liver disease. Cell Mol Immunol 2005; 2: 92-100.
27. De Smaele E, Zazzeroni F, Papa S, Nguyen DU, Jin R, Jones J et al. Induction of gadd45beta by NF-kappaB downregulates pro-apoptotic JNK signaling. Nature 2001; 414: 308-313.
28. Tang G, Minemoto Y, Dibling B, Purcell NH, Li Z, Karin M et al. Inhibition of JNK activation through NF-kappaB target genes. Nature 2001; 414: 313-317.
29. Weber A, Boege Y, Reisinger F, Heikenwalder M. Chronic liver inflammation and hepatocellular carcinoma: persistence matters. Swiss Med Wkly 2011; 141: w13197.
30. Tarrats N, Moles A, Morales A, Garcia-Ruiz C, Fernandez-Checa JC, Mari M. Critical role of tumor necrosis factor receptor 1, but not 2, in hepatic stellate cell proliferation, extracellular matrix remodeling, and liver fibrogenesis. Hepatology 2011; 54: 319-327.
31. Li Z, Yang S, Lin H, Huang J, Watkins PA, Moser AB et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003; 37: 343-350.
32. Inokuchi S, Aoyama T, Miura K, Osterreicher CH, Kodama Y, Miyai K et al. Disruption of TAK1 in hepatocytes causes hepatic injury, inflammation, fibrosis, and carcinogenesis. Proc Natl Acad Sci USA 2010; 107: 844-849.
33. Seki E, De Minicis S, Osterreicher CH, Kluwe J, Osawa Y, Brenner DA et al. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med 2007; 13: 1324-1332.
34. Knight B, Yeoh GC, Husk KL, Ly T, Abraham LJ, Yu C et al. Impaired preneoplastic changes and liver tumor formation in tumor necrosis factor receptor type 1 knockout mice. J Exp Med 2000; 192: 1809-1818.
35. Yamada Y, Kirillova I, Peschon JJ, Fausto N. Initiation of liver growth by tumor necrosis factor: deficient liver regeneration in mice lacking type I tumor necrosis factor receptor. Proc Natl Acad Sci USA 1997; 94: 1441-1446.
36. Yamada Y, Webber EM, Kirillova I, Peschon JJ, Fausto N. Analysis of liver regeneration in mice lacking type 1 or type 2 tumor necrosis factor receptor: requirement for type 1 but not type 2 receptor. Hepatology 1998; 28: 959-970.
37. Yamada Y, Fausto N. Deficient liver regeneration after carbon tetrachloride injury in mice lacking type 1 but not type 2 tumor necrosis factor receptor. Am J Pathol 1998; 152: 1577-1589.
38. Park EJ, Lee JH, Yu GY, He G, Ali SR, Holzer RG et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 2010; 140: 197-208.
39. Croft M, Benedict CA, Ware CF. Clinical targeting of the TNF and TNFR superfamilies. Nat Rev Drug Discov 2013; 12: 147-168.
40. Tilg H, Vogelsang H, Ludwiczek O, Lochs H, Kaser A, Colombel JF et al. A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis. Gut 2003; 52: 1728-1733.
41. Naveau S, Chollet-Martin S, Dharancy S, Mathurin P, Jouet P, Piquet MA et al. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology 2004; 39: 1390-1397.
42. Berres ML, Trautwein C, Schmeding M, Eurich D, Tacke F, Bahra M et al. Serum chemokine CXC ligand 10 (CXCL10) predicts fibrosis progression after liver transplantation for hepatitis C infection. Hepatology 2011; 53: 596-603.
43. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004; 5: R80.
44. Dai M, Wang P, Boyd AD, Kostov G, Athey B, Jones EG et al. Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res 2005; 33: e175.
45. Wu Z, Irizarry RA. Preprocessing of oligonucleotide array data. Nat Biotechnol 2004; 22: 656-658; Author reply 658.
46. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004; 3: 1-26.